NCT04605549: A Study of CIN-107 in Adults With Primary Aldosteronism
- State
- Completed
- Phase
- Phase 2
- People
- 15 taking part
- Started
- 8 Mar 2021
- Primary completion
- 28 Oct 2024
- Arms
- CIN-107 for dosing at 2, 4, or 8 mg (QD)
- Results
- Posted on the registry
- Papers
- doi:10.2215/cjn.0000000000000265
- 28 Oct 2020: Trial registered
- 8 Mar 2021: Trial started
- 28 Oct 2024: Trial completed
- 3 Mar 2026: Trial results posted